In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonas aeruginosa

Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents

“…Following the exclusion of additional studies that focused on interventions or therapies other than small molecule antibiotics (monoclonal antibodies, bacteriophages, metal chelators, plant extracts, Lactobacillus , etc. ), 53 studies remained ( López-Rojas et al, 2011 ; Pachón-Ibáñez et al, 2011 ; Docobo-Pérez et al, 2012 ; Tang et al, 2012 ; Wang et al, 2012 ; Yamada et al, 2012 , 2013a , b ; He et al, 2013 ; Hirsch et al, 2013 ; Jacqueline et al, 2013 ; Louie et al, 2013 , 2015 ; Harada et al, 2014 ; Hengzhuang et al, 2014 ; Yokoyama et al, 2014 ; Bowers et al, 2015 ; Cheah et al, 2015 ; Berkhout et al, 2016 ; Brunetti et al, 2016 ; Cigana et al, 2016 ; Lepak and Andes, 2016 ; Mardirossian et al, 2016 ; McCaughey et al, 2016 ; Parra Millán et al, 2016 ; Thabit et al, 2016 ; Yang et al, 2016 ; Kaku et al, 2017a , b ; Li Y. T. et al, 2017 , Li Y. et al, 2017 ; Lin et al, 2017a , b , 2018 ; Oshima et al, 2017 ; Sakoulas et al, 2017 ; Zhou J. et al, 2017 , Zhou Y. F. et al, 2017 ; Avery et al, 2018 ; Chen et al, 2018 ; de Paula et al, 2018 ; Geller et al, 2018 ; Lou et al, 2018 ; Monogue et al, 2018 ; Kirby et al, 2019 ; Ku et al, 2019 ; Nakamura et al, 2019 ; Ren et al, 2019 ; Sanderink et al, 2019 ; Zhao et al, 2019 ; Johnson et al, 2020 ; Tan et al, 2020 ; Ma X. L. et al, 2020 ; Supplementary Table 2 ). Murine model variables were extracted from these articles to generate a data set for further analyses of experimental conditions.…”

Biapenem: Clinical and Microbiological Characteristics and the Place of The New Carbapenem In The Treatment of Severe Infections In The Hospital. Clinical Pharmacologists' Point of View

“…Показано, что активность биапенема против грамотрицательных бактерий была одинакова с дорипенемом и меропенемом, но значения МПК 90 в отношении E.coli и P.aeruginosa у биапенема были ниже [18]. Более высокая активность биапенема in vitro в отношении P.aeruginosa по сравнению с другими карбапенемами показана в ряде исследований [18][19][20][21]. По сравнению с другими карбапенемами биапенем проявляет наиболее высокий бактерицидный эффект против P.aeruginosa, в том числе штаммов, формирующих биоплёнки и мутантов с несколькими эффлюксными помпами [7].…”

Effect of Stress Ulcers Prophylaxis, Sedative and Statin on Ventilator-Associated Pneumonia: A Retrospective Analysis Based on MIMIC Database

“…Ventilator-associated pneumonia (VAP) is the second most common nosocomial infection in ICU, with an incidence rate ranging from 8%–28% and a mortality rate ranging from 8%–76% ( Vincent et al, 1995 ; Rello et al, 2002 ), and patients in intensive care unit (ICU) with VAP are 1–9 times more likely to die. If the patients admitted to the intensive care unit (ICU) are complicated with VAP, the mortality rate will increase by 1–9 times ( Celik et al, 2012 ; Yamada et al, 2012 ). The presence of a tracheal tube is the most important risk factor for the development of VAP.…”